Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05934851 · ClinicalTrials.gov registry record · NA

A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia

A NA study of Vulvar Neoplasm and Dysplasia Vulvar, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
NA
Development phase
112
Enrollment target
1
Study location

NCT05934851 is a NA study of Vulvar Neoplasm and Dysplasia Vulvar that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 112 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05934851, a NA study of Vulvar Neoplasm and Dysplasia Vulvar, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
NA
Development phase
112 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare "Frozen-Section Directed Excision", which has been a proven method of surgery used in dermatology, versus the current, standard method called "Wide Local Excision" to treat high-grade vulvar dysplasia.

Interventions

  • PROCEDURE Frozen-Section Directed Excision
  • PROCEDURE Wide Local Excision

Study Locations (1)

North Carolina

  • Levine Cancer Institute - Charlotte

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2023-11-07
Est. Completion 2027-03-01
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT05934851

The ClinicalTrials.gov registry entry for NCT05934851 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Vulvar Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Frozen-Section Directed Excision is the first listed.

NCT05934851 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05934851 about?

NCT05934851 is a clinical study titled "A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia". The purpose of this study is to compare "Frozen-Section Directed Excision", which has been a proven method of surgery used in dermatology, versus the current, standard method called "Wide Local Excision" to treat high-grade vulvar dysplasia.

What is the current status of trial NCT05934851?

This trial is currently recruiting. It is a NA study. The enrollment target is 112 participants. The study started on 2023-11-07. Estimated completion is 2027-03-01.

What conditions does trial NCT05934851 study?

This clinical trial studies the following conditions: Vulvar Neoplasm, Dysplasia Vulvar.

What interventions are being tested in trial NCT05934851?

The interventions under investigation include: Frozen-Section Directed Excision (PROCEDURE), Wide Local Excision (PROCEDURE).

Who is sponsoring clinical trial NCT05934851?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05934851 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.